Therapeutic area |
Neuro-protection |
Goal |
To further characterize the molecular pharmacology of the CIGB-845 neuro-protective effects toward its clinical use as a neuro-protective agent. |
Description |
CIGB-845 is a pharmacological combination between a synthetic peptide and a protein, endowed with neuro-protective and neurorestaurative properties, both with a substantial safety profile. Different experiments conducted by our group have shown that a single pre-conditioning or multiple CIGB-845 therapeutic administrations were able to protect the SNC and elicit neuro-protective mechanisms during experimental autoimmune encephalitis episodes and other experimental axonopathy models of amyotrophic lateral sclerosis disease.
|
Patent Status |
Patent filed: CU2005-0043. |
Project Status |
Development and preclinical.
|
Type of collaboration requested |
Corporate partnership for joint development.
|
Competitives advantages Milestones |
This is focused to be the first medication aimed at:
1. Avoid progression in Amyotrophic Lateral Sclerosis patients
2. Ameliorate or avoid exacerbation or relapses in Multiple Sclerosis patients.
Development and preclinical will finish this year.
|
Host Insitutions |
Center for Genetic Engineering and Biotechnology (CIGB). Ave 31, e/158 y 190 Cubanacán, Playa. PO Box 6996, Havana, 10600, Cuba. Tel. (53-7) 2712397; 2716022. Fax. (53-7) 336008; 2718070. E-mail: ernesto.lopez@cigb.edu.cu.
Web site: http://gndp.cigb.edu.cu.
|
Project code:
|
BIO/CIGB/2008-15
|
